semaglutide patent expiration 2031 Off-patent in 2026: the next revolution in anti-obesity medications semaglutide patent expiration us 2031

Positive topline data announced in April showed that the trial met its primary endpoints using both the treatment-regimen* and efficacy estimands

The identification of the pleiotropic SNP PMSnpB394 , associated with 14 vigor and longevity-related traits, highlights genomic regions of major effect influencing seed performance and viability

These numbers exceeded the Phase 2 results, partly because the trial ran longer (68 weeks versus 48 weeks) and partly because the dose escalation schedule was refined

Tirzepatide, semaglutide, liraglutide, and, to a lesser extent, naltrexonebupropion provided significant improvement in glycemic parameters and variable rates of type 2 diabetes remission 6 (Table 1)

Reduced HRV during the early treatment phase is expected and typically normalizes during the adaptation phase